Case Report - (2025) Volume 11, Issue 2
Extranodal Natural Killer/T-cell Lymphoma (ENKTCL)-associated Hemophagocytic Syndrome (HPS) is a rare and fatal disease. Chemotherapy was commonly used but the efficacy was dismal. Although immunotherapy with immune checkpoint inhibitors was effective in NK/T cell lymphoma, the use of immunotherapy in introduction treatment of HPS was controversial with concern on side effects. We report a case of HPS who was treated with immunotherapy instead of chemotherapy for HPS. The patient achieved complete remission, confirming that immunotherapy is an effective treatment approach for patients with ENKTCL-associated HPS.
Yabing Cao Department of Oncology, Kiang Wu Hospital, Macau, China E-mail: scaoyabing@kwh.org.mo
Abstract
Extranodal Natural Killer/T-cell Lymphoma (ENKTCL)-associated Hemophagocytic Syndrome (HPS) is a rare and fatal disease. Chemotherapy was commonly used but the efficacy was dismal. Although immunotherapy with immune checkpoint inhibitors was effective in NK/T cell lymphoma, the use of immunotherapy in introduction treatment of HPS was controversial with concern on side effects. We report a case of HPS who was treated with immunotherapy instead of chemotherapy for HPS. The patient achieved complete remission, confirming that immunotherapy is an effective treatment approach for patients with ENKTCL-associated HPS.
Citation: Cao Y. "Use of Immunotherapy in Introduction Therapy of Hemophagocytic Syndrome Induced by Extranodal NK/T-Cell Lymphoma: Case Report". Oncol Cancer Case Rep, 2025, 11(1), 1-2.
Received: 09-May-2024, Manuscript No. OCCRS-24-134415; Editor assigned: 11-May-2024, Pre QC No. OCCRS-24-134415 (PQ); Reviewed: 25-May-2024, QC No. OCCRS-24-134415; Revised: 13-Mar-2025, Manuscript No. OCCRS-24-134415 (R); Published: 20-Mar-2025, DOI: 10.35248/2471-8556.25.11(1).001-010
Copyright: © 2025 Cao Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.